Background
The ability to hear is important, particularly during children's formal education. Hearing impairment is amenable to intervention and hence a screening programme when children begin their school careers has potential value. School entry hearing screening (SES) has been implemented throughout the UK since the 1950s. There is evidence of mixed practice and uncertainty about the value of the screen. In addition, recent changes in childhood hearing screening policy (abandonment of a screen at 8 months and introduction of universal newborn screening) have implications for identification of children with hearing impairment at school entry.
Objectives
This report aimed to determine answers to the following three questions:
• What is current practice for the SES in the UK?
• What is known about the accuracy of alternative screening tests and the effectiveness of interventions? • What is known about costs, and what is the likely cost-effectiveness of the SES?
Methods
A national postal questionnaire survey was addressed to all leads for the SES in the UK, considering current practice in terms of implementation, protocols, target population and performance data. Primary data from cohort studies in one area of London were examined. A systematic review of alternative SES tests, test performance and impact on outcomes was carried out. Finally, a review of published studies on costs, plus economic modelling of current and alternative programmes was prepared.
Results
The evidence from the national survey of current practice is that: impact on the quality of the screen.
The evidence from the primary cohort studies is that:
• the prevalence of permanent childhood hearing impairment continues to increase through infancy • of the 3.47 in 1000 children with a permanent hearing impairment at school screen age, 1.89 in 1000 required identification after the newborn screen • the introduction of newborn hearing screening is likely to reduce significantly the yield of SES for permanent bilateral and unilateral hearing impairments; yield had fallen from about 1.11 in 1000 before newborn screening to about 0.34 in 1000 for cohorts that had had newborn screening, of which only 0.07 in 1000 were unilateral impairments • just under 20% of permanent moderate or greater bilateral, mild bilateral and unilateral impairments, known to services as 6-year-olds or older, remained to be identified around the time of school entry.
The evidence from the systematic review of the alternative tests and of the effectiveness of interventions is that:
Executive summary: School entry hearing screen Executive summary
• no good-quality published comparative trials of alternative screens or tests for school entry hearing screening were identified • studies concerned with the relative accuracy of alternative tests are difficult to compare and often flawed by differing referral criteria and case definitions; with full pure tone audiometry as the reference test, the pure tone sweep test appears to have high sensitivity and high specificity for minimal, mild and greater hearing impairments, better than alternative tests for which evidence was identified • there is insufficient evidence to draw any conclusions about possible harm of the screen • there were no published studies identified that examined the possible effects of SES on longer term outcomes.
The evidence from the cost-effectiveness study is that:
• no good-quality published economic evaluations of SES were identified • a universal SES based on pure tone sweep tests was associated with higher costs and slightly higher quality-adjusted life-years (QALYs) compared with no screen and other screen alternatives; the incremental cost-effectiveness ratio for such a screen is around £2500 per QALY gained; the range of expected costs, QALYs and net benefits was broad, indicating a considerable degree of uncertainty • targeted screening could be more cost-effective than universal SES • lack of primary data and the wide limits for variables in the modelling mean that any conclusions must be considered indicative and exploratory only.
A national screening programme for permanent hearing impairment at school entry meets all but three of the criteria for a screening programme, but at least six criteria are not met for screening for temporary hearing impairment.
Conclusions
The lack of good-quality evidence in this area remains a serious problem. Services should improve quality and audit screen performance for identification of previously unknown permanent hearing impairment, pending evidence-based policy decisions based on the research recommendations.
Recommendations for research
Further research is highlighted in the following areas:
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